Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents

Abstract

At 13 months, the new-generation zotarolimus-eluting stent was found to be noninferior to the everolimus-eluting stent in a population of patients who had minimal exclusion criteria. (ClinicalTrials.gov number, NCT00617084.)